Cruite Justin T, Nowak Radosław P, Donovan Katherine A, Ficarro Scott B, Huang Huang, Liu Hu, Liu Yingpeng, Marto Jarrod A, Metivier Rebecca J, Fischer Eric S, Jones Lyn H
Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
ACS Med Chem Lett. 2023 Oct 24;14(11):1576-1581. doi: 10.1021/acsmedchemlett.3c00371. eCollection 2023 Nov 9.
Site-specific modification of amino acid residues in protein binding pockets using sulfonyl exchange chemistry expands the druggable proteome by enabling the development of covalent modulators that target residues beyond cysteine. Sulfonyl fluoride and triazole electrophiles were incorporated previously into the cereblon (CRBN) molecular glue degrader EM12, to covalently engage His353 within the CRBN sensor loop, but these probes had poor human plasma stability. Attenuation of intrinsic reactivity through the development of sulfonyl pyrazoles, imidazoles, and nucleobases enhanced plasma stability, and several compounds retained efficient labeling of His353. For example, sulfonyl imidazole EM12-SOIm covalently blocked the CRBN binding site and possessed excellent metabolic stability in human plasma, liver microsomes, and hepatocytes. These results highlight the potential suitability of sulfonyl imidazole and related sulfur(VI)-diazole exchange (SuDEx) warheads for covalent drug development and further exemplify the therapeutic promise of site-specific histidine targeting.
利用磺酰基交换化学对蛋白质结合口袋中的氨基酸残基进行位点特异性修饰,通过开发针对半胱氨酸以外残基的共价调节剂,扩大了可成药蛋白质组。先前已将磺酰氟和三唑亲电试剂引入到脑啡肽(CRBN)分子胶降解剂EM12中,以共价结合CRBN传感环内的His353,但这些探针在人血浆中的稳定性较差。通过开发磺酰基吡唑、咪唑和核碱基来减弱内在反应性,提高了血浆稳定性,并且几种化合物保留了对His353的有效标记。例如,磺酰基咪唑EM12-SOIm共价阻断了CRBN结合位点,并且在人血浆、肝微粒体和肝细胞中具有优异的代谢稳定性。这些结果突出了磺酰基咪唑和相关的硫(VI)-二唑交换(SuDEx)弹头在共价药物开发中的潜在适用性,并进一步例证了位点特异性组氨酸靶向的治疗前景。